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Background: As high percentage of mammographic densities complicates the assessment of imaging findings,
mammographic density may influence the histopathological evaluation of core-biopsies of the breast. We measured
the influence of mammographic density on the inter-observer variability of histopathological findings of breast
biopsies.
Methods: Histological slides of 695 women who underwent core biopsies of the breast at University of Halle
between 2006 and 2008 were evaluated in a blinded fashion by two pathologists using the five levels of the
B-categorization scheme (B1-B5). To quantify mammographic density, we used a computer-based threshold
method (Madena). We calculated observed and chance-corrected agreements (weighted kappa) and 95%
confidence intervals (95% CI) according to four categories of mammographic density (<10%, 10<25%, 25<50%,
≥50%).
Results: The weighted kappa decreased monotonically from 89.6% (95% CI: 85.8%, 93.3%) among women with less
than 10% of mammographic density to 80.4% (95% CI: 69.9%, 90.9%) for women with more than 50% of
mammographic density, respectively. Results of a kappa regression analysis showed that agreement of pathologists
on clinically relevant categories (B1-B2 versus B3-B5) decreased with mammographic density.
Conclusions: Mammographic density is a relevant modifier of the agreement between pathologists who assess
breast biopsies using the B-categorization scheme. The influence of mammographic density on the inter-observer
variability can be explained to some extent by varying prevalences of histological entities across B categories that
have typically different inter-observer agreement. Women with high mammographic density are at higher risk of
inter-observer variability compared to women with low mammographic density and should possibly undergo a
second pathology review.
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The breast is composed of a mixture of fibroglandular
tissue that appears bright on a mammogram (radio
dense) and fatty tissue that appears radiological transpar-
ent (radiolucent). The radiological appearance of fibro-
glandular breast tissue is quite similar to that of breast
lesions. Therefore, high mammographic density may
mask breast lesions and reduce the probability that can-
cerous lesions are detected. Mammographic density is a
well described indicator of increased risk of breast can-
cer and may be related to the degree of diagnostic cer-
tainty [1,2].
Several studies have shown that mammographic dens-
ity is negatively associated with the performances of
breast cancer screening. In a United Kingdom’s study
Carney et al. reported that the sensitivity of mammog-
raphy decreased from 87% in women with almost en-
tirely fatty breasts to 62.9% in women with extremely
dense breasts [3]. Britton et al. observed a reduction of
mammographic sensitivity with increasing mammo-
graphic density according to a four category density clas-
sification [4]. As high mammographic density
complicates the assessment of the imaging findings and
the histopathological diagnostic should be performed in
correspondence with the mammographic findings, a
high mammographic density may be associated with
higher inter-observer variability between pathologists
who evaluate biopsy material. To date, no studies have
reported results about the influence of mammographic
density on the reliability of histopathological findings of
breast biopsies that are currently classified by the B-
categorization according to the National Coordinating
Group for Breast Screening Pathology [5]. The B-
categorization includes five reporting categories. Cat-
egories B1-B2 usually do not require further invasive
diagnostic workup unless biopsies classified as B1 were
uninterpretable or unrepresentative of the breast lesion
according to the imaging and clinical findings. Categor-
ies B3-B5 usually require further invasive workup. The
European guidelines recommend to check that the histo-
logical findings correlate with the mammographic find-
ings in order to interpret correctly the histological
material of core biopsies of the breast and before to de-
fine the diagnosis [6].
To assess mammographic density patterns, both quali-
tative and quantitative approaches have been used.
Wolfe described first in 1976 a qualitative method to as-
sess mammographic density using a classification of the
breast tissue based on the description of four
parenchyma-patterns of the breast that defines four level
of mammographic density [7]. More recently, the Ameri-
can College of Radiology (ACR) developed in 1993 the
Breast Imaging Reporting and Data System (BIRADS), a
classification of breast tissue density that is also basedon four categories of mammographic density (I: mostly
fatty, II: fibroglandular, III: heterogeneous dense, IV: ex-
tremely dense) with the aim of increasing the uniformity
in interpretations of mammographic findings [8]. How-
ever, according to the results of a study of Kerlikowske
et al. in 1998, there is considerably variability in inter-
preting mammographic density by applying this method
[9]. Ciatto et al. reported in 2005 that the interobserver
agreement on assessing breast densities according to
BIRADS was “moderate” (Kappa=0.54) [10]. In our
study, we used a computer-assisted method of assessing
mammographic density [11].
The aim of this study was to assess the influence of
mammographic density estimated by a quantitative scale
on the inter-observer variability of the pathologic evalua-
tions of core-biopsies of the breast.
Methods
The design and first results of the study were described
in detail previously [12,13]. The Diagnosis Optimisation
Study (DIOS) was approved by the institutional review
board of the Medical Faculty of the Martin-Luther-
University of Halle-Wittenberg.
In brief, we recruited women who underwent core bi-
opsies of the breast at the Department of Radiology be-
tween April 2006 and August 2008. All women provided
an informed consent for participation in the study. As
women of the organized mammography screening pro-
gram who were biopsied by ultrasound guidance were
not referred to the university they were not eligible for
this study. Overall, 30 women were not eligible for sev-
eral reasons: core biopsy technically impossible (N=22),
microcalcification of the skin (N=3), lack of sufficient
command of the German language (N=3), and other rea-
sons (N=2). A total of 98 women refused to participate.
An additional 29 women only partially agreed to partici-
pate. Partial agreement included histopathological as-
sessment by the pathologists but excluded the
questionnaire-based assessment of breast cancer risk
factors, including weight and height of the women.
Women below the age of 18 were excluded from the
study. For 66 women, mammographic density assess-
ment was technical impossible and, therefore, these
women were excluded from the analysis, giving a final
study population which included 695 women.
As in our previous publication [13], we defined four
groups of women who were referred to the university for
further work-up of imaging abnormalities of the breast
(“referral groups”): women referred from the organized
mammography screening program in Halle for stereotac-
tic core biopsy (“screening”), women with a history of
breast cancer with abnormal follow-up breast images
(“history of breast cancer”), women with clinical symp-
toms of the breast (“clinical symptoms”) and women
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outside the screening program (“only images”). The
available pre-biopsy imaging findings including mam-
mographic density were recorded from the radiologists
according to the four categories of the Breast Imaging
Reporting and Data System (BIRADS) of the American
College of Radiology (I, II, III and IV). The level of
suspicion of the lesions were documented on a scale
of 0 to 6 including “additional imaging evaluation
recommended” (BIRADS-code 0), “negative (no abnormal
lesions)” (BIRADS-code 1), “benign lesions” (BIRADS-
code 2), “probably benign lesions” (BIRADS-code 3),
“suspicious abnormality” (BIRADS-code 4), “highly sug-
gestive of cancer” (BIRADS-code 5), and “biopsy-proven
malignancy” (BIRADS-code 6). Biopsies were performed
by either stereotactic-, ultrasound- or magnetic
resonance-guided vacuum-assisted methods or by the
ultrasound-guided automated gun method. The choice of
imaging technique for the biopsies depended on the de-
tection method of the breast abnormality, and the size
and type of lesion. Histological slides of the biopsies
were assessed by overall three pathologists. First, the
local pathologist at the Martin-Luther-University of Halle
(Pathologist 1, H.J.H.) reviewed the haematoxylin and
eosin-stained (HE) slides from paraffin-embedded blocks
of the biopsy specimens. If necessary to confirm the
diagnosis or to define receptor status, immunhistochem-
ical (IHC) staining was performed. Second, in order to
implement a reference standard, a second pathologist
(W.B.) reviewed the material and made the reference
diagnosis. Disagreements between the local and reference
pathologist were resolved by consensus based on a tele-
phone conference. Third, the pathologist from the
Albertinen-Pathology Hamburg (Pathologist 2, T.L.)
evaluated in a blinded fashion the identical set of slides
that had been assessed by the pathologist of the Univer-
sity of Halle. To estimate the interobserver agreement
between the histopathological evaluations of the biop-
sies, we compared the assessments of pathologist 1 and
2, since the reference pathologist was not fully blinded
against the diagnosis of pathologist 1 and had the op-
portunity to perform additional IHC staining to confirm
the diagnosis.
The radiologists who undertook the core biopsy pro-
vided information about age, localization of biopsy,
number of biopsy cores, microcalcification, and a de-
scription of the focus. Furthermore, for women with
microcalcification, the pathologists received the X-ray
images of the paraffin blocks containing the biopsy spe-
cimen. The result of the core biopsy was interpreted in
relation to the imaging findings (i.e. mammography,
ultrasound or magnetic resonance image depending on
the radiologic technique). The histopathological findings
were documented on a standardized case report formthat included both the traditional diagnosis of the histo-
logical findings and the B-categories (B1: normal or un-
interpretable, B2: benign, B3: benign but of uncertain
biological potential, B4: suspicious of malignancy, and
B5: malignant including in-situ and invasive cancer. Cat-
egory B5 is further subcategorized into B5a (in situ), B5b
(invasive), B5c (uncertain whether it is in-situ or inva-
sive), and B5d (other malignancies). This scheme is
recommended by the European Guidelines for quality
assurance in mammography screening and among
women with symptomatic breast lesions with the aim of
standardizing histopathological reporting [5,6]. After
histopathological evaluation, it was documented,
whether the histopathological findings correlated with
the imaging findings.
To assess mammographic density on a quantitative
scale, we used the Madena computer-based threshold
method, a method that has been validated and described
previously [11,14]. Mammographic images were digitized
using a scanner (VIDAR’s DiagnosticPro Advantage film
digitizer) and were then viewed on a computer screen.
With few exceptions, we read the craniocaudal mammo-
gram selected from the unaffected breast. In brief the as-
sessment was carried out as follows: The image was
imported to Madena and the total area of the breast was
outlined by a reader trained by an experienced reader
(G.U.) using a special computerized outlining tool and
the software estimated the total number of pixels in the
breast. This measurement corresponds to the total
breast area. Second, the reader defined a region of inter-
est in the breast that contains dense tissue, with excep-
tion of the areas corresponding to the pectoralis muscle,
prominent veins, fibrous strands and other light arte-
facts. The reader then used a tinting tool to make dense
areas within the region of interest that have a threshold
intensity of grey at or above a pixel value of X and below
a pixel value of 255. The computer program assigns a
pixel value within a range between zero for the darkest
shade of the image and 255 for the lightest shade of the
image. The reader searches for the threshold that
enables best assessment of mammographic densities.
The total number of tinted pixels within the region of
interest represents the absolute area of mammographic
density. The percent of mammographic density equals to
the ratio of the dense area to the total area of the breast
in the mammogram. The readers were blinded to all
subject characteristics.Statistical analysis
To quantify mammographic density, we measured both
the absolute area of the breast that appeared dense and
the proportion of mammographic image representing
radiographically dense breast. We categorized the
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classes (Figure 1: <10%, 10-<25%, 25-<50%, ≥50%).
To evaluate the B-categorization agreement between
the pathologists, we estimated observed and chance-
corrected agreements (weighted kappa) and 95% confi-
dence intervals (95% CI). We estimated measures of
agreement using the five levels of the B-categorization
scheme (B1-B5). Clinically relevant categories which
imply the subsequent use of different therapeutic strat-
egies are B1-B2 (usually require no further work-up) and
B3-B5 (usually require further invasive work-up). To as-
sess the influence of breast density on agreement of the
pathologists (as measured as agreement on B1-B2 versus
B3-B5), we ran a kappa regression model [15]. This
model allows the estimated kappa coefficient to vary for
different values of breast density while additionally
adjusting for covariates. To communicate results from
this model we estimated kappa values for the range of
observed values of mammographic density with their
95% confidence intervals. Furthermore, we assessed the
association between percentage of mammographic dens-
ity and potential determinants of radiological mammo-
graphic density, including age and body mass index
(BMI).
180 out of 695 women underwent more than one core
biopsy of the breast. To avoid a statistical dependency
between these biopsies, we only analysed data of the first
biopsies of these women. All statistical analyses were
performed with SAS 9.2.
Results
The analysis included 695 women. Table 1 shows the
characteristics of the study subjects. The mean age at biopsy
was 56.1 years, the mean BMI was 26.6 kg/m2. Overall, 55%
of the women underwent a mammographic-guided coreFigure 1 Categories of percentage of mammographic density accordi
B: 10<25%; C: 25<50%; D: ≥50%).biopsy, 28% underwent a sonographic-guided biopsy and
17% underwent a MRI-guided core biopsy. The median
percentage of breast tissue with densities was 18% (mean
percent density: 23%). The median area of breast with
mammographic densities was 154 cm2 (mean area: 301
cm2). The prevalence of diagnoses categorized as B5
according to the reference standard was overall 30.4% and
decreased progressively from 38.8% for women with less
than 10% density to 12.8% for women with more than 50%
(Table 2).
The comparison of the results of the mammographic
density assessment based on the quantitative computer-
assisted method and those based on the qualitative
method developed from the American College of Radi-
ology (ACR) revealed that higher percentage of mammo-
graphic density was associated with higher ACR
category of mammographic density (Table 3). The me-
dian percentage of mammographic density ranged from
1% for women with breasts that were “mostly fatty”
(ACR I) to 50% for women with ACR category “dense”
(ACR IV). Figures 2 and 3 show that the percent density
was negatively associated with age and BMI. The median
percent density decreased from 39% respectively for
women aged less than 40 years to 10% respectively for
women aged more than 70 years. The median percent
density decreased from 31% among women with BMI
lower than 21 kg/m2 to 6% among women with BMI
higher than 30 kg/m2. About three out of four women
(76%) in the lowest group of percent density (lower than
10% density) had BMI higher than 25 kg/m2.
Overall, the observed and the chance-corrected agree-
ment based on the five levels of the B-categorization
scheme were 85.5% (95% CI: 82.6%, 88.0%) and 87.9%
(95% CI: 85.5%, 90.3%), respectively. Table 4 shows that
the inter-observer agreement was inversely associatedng to the computer-assisted assessment method (A: <10%;
Table 1 Characteristics of women who underwent core
biopsy at Martin-Luther-University of Halle (Saale),



















History of breast cancer 90 13.0
Clinical symptoms 128 18.4







Radiological focus 396 57.0
Microcalcification 346 49.8
Mammographic breast density (ACR)
almost entirely fatty 58 8.4
fibroglandular 282 41.0
heterogenous dense 283 41.1
extremely dense 65 9.5
Mammographic breast density (Computer-based assessment)
<10% 242 34.8
10% to <25% 181 26.0
25% to <50% 186 26.8
≥50% 86 12.4
Table 2 Frequency distribution of B-categorized biopsies
according to the reference diagnosis (Reference
standard-B)
Density (%) Women B1 B2 B3 B5
N % N % N % N %
<10% 242 20 8.3 108 44.6 20 8.3 94 38.8
10 to <25% 181 14 7.7 86 47.5 28 15.5 53 29.3
25 to <50% 186 19 10.2 83 44.6 31 16.7 53 28.5
≥50% 86 5 5.8 65 75.6 5 5.8 11 12.8
Overall 695 58 8.4 342 49.2 84 12.1 211 30.4
Table 3 Percentage of mammographic density of the
study subjects by categories of mammographic density
based on the Breast Imaging Reporting and Data System
(BIRADS) of the American College of Radiology
ACR category N Percent density
Mean Median
Mostly fatty (ACR I) 58 3 1
Fibroglandular (ACR II) 282 11 8
Heterogeneously dense (ACR III) 283 33 31
Dense (ACR IV) 65 52 50
Missing evaluations 7 22 13
Overall 695 23 18
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weighted kappa decreased monotonically from 89.6%
(95% CI: 85.8%, 93.3%) among women with less than
10% of mammographic density to 80.4% (95% CI: 69.9%,
90.9%) for women with a mammographic density of 50%
or more, which corresponds to an estimated absolutedifference of 9.2% points (95% CI: −2.0%, 20.3%). The
observed agreement decreased from 87.6% (95% CI:
82.8%, 91.5%) among women in the lowest category to
82.6% (95% CI: 72.9%, 89.9%) for women in the highest
category of percent density. The median percent of
mammographic density among women for whom there
was agreement on the B-category of the diagnosis was
lower by 4% points compared to subjects for whom
there was no agreement between the pathologists (22%
vs. 18%).
Figure 4 shows that agreement of the pathologists on
B1-B2 versus B3-B5 decreased with mammographic
density. To explore the reasons of this decrease, we cal-
culated the frequency of B2-B3 disagreements according
to level of mammographic density. We found that the
number of B2-B3 disagreements increased with mam-
mographic density more than the disagreements overall
(data not shown). Adjustment for mammographic find-
ings and level of suspicion of the lesions (BIRADS-code)
did not change these results.
Among 34 study participants, the histological findings
did not correlate with imaging findings. These women
had a higher percent-density (median 27%) and area of
mammographic density (median 343 cm2) compared to
women for whom the correlation between histologic and
imaging findings was observed (median percent-density:
17%, median area of density: 140 cm2).
Figure 2 Distribution of percent densities among the 695 study subjects of the DIOS-Study 2006–2008 according to age group. Box
width varies with age group size. Whiskers indicate observations between the lower and upper fence [i.e. 1.5*interquartile range (IQR) below 25th
percentile and 1.5*IQR above 75th percentile]. Plus symbols indicate observations outside the fences. Filled squares indicate mean percent density
values. Horizontal lines within the boxes indicate the median percent density values.
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Our study shows that a higher percentage of mammo-
graphic density is associated with lower inter-observer
agreement of the histopathological evaluation of core bi-
opsies of the breast using the B-categorization. The
weighted kappa for women with very low percentage of
mammographic density (less than 10%) was 9.2% points
(95% CI: -2.0%; 20.3%) higher than the weighted kappa
for women with mammographic density of 50% or more.
Our findings suggest that women with radiological
breast densities are at higher risk of disagreement and, if
possible, should undergo more than one pathology
review.
Mammographic density complicates the evaluation of
the imaging findings because the radiological appearance
of the fibroglandular breast tissue and that of the mam-
mographic abnormalities can be very similar. Due to aFigure 3 Distribution of percent densities among the 695 study subje
(BMI). Box width varies with age-group size. Whiskers indicate observation
below 25th percentile and 1.5*IQR above 75th percentile]. Plus symbols indi
percent density values. Horizontal lines within the boxes indicate the medimasking effect of cancers by dense breast tissue, a higher
mammographic density decreases the sensitivity of
mammographic diagnostic, which is to say that increases
the risk that a carcinoma will be obscured on the mam-
mogram. We found that the prevalence of carcinomas,
according to the reference standard, decreased with
mammographic density. Therefore, as carcinomas of the
breast are typically lesions with a high inter-observer
agreement, the association between high mammographic
density and low inter-observer agreement can be par-
tially explained by the lower prevalence of B5-categories
among women with higher percentage of mammo-
graphic density. The results of the regression analysis
imply that the probability of agreement on categories
that usually require no further work-up (B1-B2) versus
categories that usually require invasive work-up (B3-B5)
was modified by the percentage of mammographiccts of the DIOS-Study 2006–2008 according to body mass index
s between the lower and upper fence [i.e. 1.5*interquartile range (IQR)
cate observations outside the fences. Filled squares indicate mean
an percent density values.
Table 4 Percent of observed agreement and chance-
corrected agreement (weighted kappa values) of
histopathological evaluation (five level B-categorization)
according to percent of mammographic density
Percent density N Agreement (95% CI)
Observed Kappa
<10% 242 87.6 (82.8-91.5) 89.6 (85.8-93.3)
10% to <25% 181 86.2 (80.3-90.9) 88.2 (83.5-92.8)
25% to <50% 186 83.3 (77.2-88.4) 86.4 (81.6-91.2)
≥50% 86 82.6 (72.9-89.9) 80.4 (69.9-90.9)
Overall 695 85.5 (82.6-88.0) 87.9 (85.5-90.3)
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gest that this decrease is due to an increasing frequency
of disagreements about the neighbouring B categories
B2 and B3 that encompass histological lesions for which
the choice of the appropriate therapeutic strategy is
most problematic. As expected, women for whom the
histological lesions did not correlate to the mammo-
graphic abnormalities had a substantially higher percent
density in comparison to women for whom the histo-
logic and the imaging findings were correlated (median:
27% vs. 17%). To perform the histopathological assess-
ment of the breast biopsy, according to the European
Guidelines, the radiological findings are compared with
the histological appearance of biopsy specimens in order
to verify the representativeness of the biopsy. Therefore,
as high mammographic density complicates the task of
the pathologist to ensure that histological findings are
representative for imaging findings, high mammographic
density decreases the probability to observe inter-Figure 4 Chance-corrected agreement (weighted kappa values) of his
percent of mammographic density. Note: Categories B3-B5 usually requiobserver agreement between pathologists who review bi-
opsy material.
We provide evidence that the percentage of the breast
area with densities decreases progressively with age and
BMI of the women. These results are consistent with
those of several other studies [1,16]. Therefore, age and
BMI may be considered as modifiers of the level of
interobserver agreement of evaluations of breast biop-
sies, as these factors influence mammographic density.
Finally, we observed a positive association between the
results of the mammographic density assessment based
on the classification system developed by the American
College of Radiology (BIRADS) and those based on the
computer-assisted method used in this study. Several
studies on the assessment of ACR-based density
categorization have shown that the inter- and intra-
observer variability of interpretations of mammographic
densities is only moderate [9,10]. Computer-assisted
methods provide a measure of the projected area of
dense tissue on a continuous scale and could represent a
less subjective alternative to categorical methods of
quantifying breast densities.
Our study has some limitations. First, the histological
slides were reviewed in a blinded fashion by only two
pathologists experienced breast pathologists. However,
certified breast cancer centers in Germany and other
countries request experienced pathologists who are cer-
tified in the evaluation of core biopsies of the breast.
Second, as the computer-based method to assess mam-
mography density measurement is not completely auto-
matically done, some measurement error of the
mammography density may have occurred. To minimizetopathological evaluation and probability of B3-B5 according to
re further invasive work-up.
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measured several thousand mammograms before this
study did all readings in a centralized way for this study.
Conclusions
Mammographic density is a relevant modifier of the
agreement between pathologists who assess breast biop-
sies using the B-categorization scheme. The influence of
mammographic density on the inter-observer variability
can be explained to some extent by the prevalence of
histological entities that have different inter-observer
agreement. Our findings suggest that women with radio-
logical breast densities are at higher risk of disagreement
compared to women with low mammographic density
and, if possible, should undergo more than one path-
ology review.
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